Australia - inglese - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - nortriptyline hydrochloride, quantity: 11.4 mg (equivalent: nortriptyline, qty 10 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - treatment of major depression

Australia - inglese - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - nortriptyline hydrochloride, quantity: 28.5 mg (equivalent: nortriptyline, qty 25 mg) - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate - treatment of major depression

Australia - inglese - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Stati Uniti - inglese - NLM (National Library of Medicine)

tya pharmaceuticals - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 25 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infarc

Australia - inglese - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 500 iu; factor x, quantity: 500 iu; factor ii, quantity: 500 iu - injection, diluent for - excipient ingredients: water for injections - prothrombinex-vf is indicated in - treatment and perioperative prophylaxis of bleeding in acquired deficiency of prothrombin complex factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required. - treatment and prophylaxis of bleeding in patients with single or multiple congenital deficiency of factor ix, ii or x when purified specific coagulation factor product is not available (see precautions).